Post-Menopausal Dyspareunia: Optimizing Patient Outcomes Through Innovations in Diagnosis and Therapy

Post-Menopausal Dyspareunia: Optimizing Patient Outcomes Through Innovations in Diagnosis and Therapy

Post-Menopausal Dyspareunia: Optimizing Patient Outcomes Through Innovations in Diagnosis and Therapy
RestartResume
    ECHO™ A CME Self-Study Activity: Post-Menopausal Dyspareunia: Optimizing Patient Outcomes Through Innovations in Diagnosis and Therapy

    Available credits: 0.25

    Time to complete: 15 minutes

    Released:

    Valid until:

    Take Post-Test

    If you’ve already completed the activity.

    • Overview

      Vulvar vaginal atrophy (VVA) affects about half of the 64 million postmenopausal women in the U.S. VVA is the loss of estrogen stimulation on vaginal and vulvar tissue, resulting in atrophy of these tissues and these women may suffer from symptoms, which include dyspareunia - or painful sexual intercourse. With this, dyspareunia can negatively impact a woman’s sexual function and sexual relationships, in addition to her overall quality of life.

      This article will define VVA and genitourinary syndrome (GSM), their pathophysiology and impact on post-menopausal dyspareunia. Also covered will be both the clinician-based and patient-based factors that may impact the diagnosis and treatment of dyspareunia as well as the clinical trial data from recent pivotal studies of innovative therapies indicated for the management of menopause-related dyspareunia.

    • Disclosure of Conflicts of Interest

      In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

       Reviewers/Planners/Authors:

      • Sean T. Barrett has nothing to disclose.
      • Carole Drexel, PhD, CHCP has nothing to disclose.
      • Amanda Hilferty has nothing to disclose.
      • Ashley Rosenthal has nothing to disclose.
      • Lynne Kolton Schneider, PhD has nothing to disclose.
      • Robert Schneider, MSW has nothing to disclose.
    • Learning Objectives

      After participating in this educational activity, participants should be better able to:

      • Define vulvovaginal atrophy (VVA), and genitourinary syndrome (GSM), their pathophysiology and impact on post-menopausal dyspareunia
      • Identify the factors, both clinician-based and patient-based, that may impact diagnosis and treatment of dyspareunia
      • Review clinical trial data from recent pivotal studies of innovative therapies indicated for the management of menopause-related dyspareunia
    • Target Audience

      This activity is designed to meet the educational needs of the obstetrician and gynecologist, family physician, internal medicine physician, physician assistant, nurse practitioner, and certified nurse midwife.

    • Accreditation and Credit Designation Statements

      The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

      The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    • Provider

      Omnia Education has a core focus on women's health and the ways in which diseases and conditions impact the female patient. That unique focus has transformed the CME learning environment for healthcare professionals nationwide. We impact thousands of clinicians annually, many of whom return each year for clinical updates and connectivity with regional peers.

    • Commercial Support

      This activity is supported by an independent educational grant from AMAG Pharmaceuticals.

    • Disclaimer

      The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of TOPEC and Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Omnia Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

      Reproduction Prohibited

      Reproduction of this material is not permitted without written permission from the copyright owner.

    • System Requirements

      Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

    Facebook Comments

    Sign-up for the Omnia Education newsletters.
    Comprehensive women’s health CME.

    Better education for a better you.

    * Required
    Optional
    Register

    Join Omnia Education's community of women's health professionals.
    Registration is free and easy.

    Register Now